CLTA

Across TCGA pan-cancer cohorts, CLTA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLTA data layer compared with 27 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CLTA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CLTA expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

UCEC, PDAC, and LUAD are the cancer types where CLTA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	1.000	0.345	.007	24	view →
PDAC	OS	Median	IV	0.951	0.381	.006	7	view →
LUAD	DFS	Median	II,III,IV	0.913	0.756	.019	5	view →
CCRCC	DFS	Median	IV	0.932	0.382	.031	5	view →
GBM	DFS	Quartile	All	0.875	0.681	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLTA–UCEC (DFS)

Open the UCEC breakdown →